Drugs & Targets Dewpoint Therapeutics and ConcertAI form drug development partnership December 13, 2024Vol.50 No.46
Drugs & Targets FDA grants accelerated approval to zenocutuzumab-zbco for NSCLC and pancreatic adenocarcinoma December 06, 2024Vol.50 No.45
Drugs & Targets Merus and Partner Therapeutics announce license agreement for the U.S. commercialization of zenocutuzumab in NRG1 fusion-positive cancer December 06, 2024Vol.50 No.45
Drugs & Targets ConcertAI and NeoGenomics announce AI software-as-a-service solution for hematology clinical research December 06, 2024Vol.50 No.45
Drugs & Targets FDA approves new alternative standard related to mammography report assessments November 22, 2024Vol.50 No.44
Drugs & Targets FDA approves revumenib for r/r acute leukemia with a KMT2A translocation November 22, 2024Vol.50 No.44
Drugs & Targets FDA approves first companion diagnostic for lung cancer drug November 22, 2024Vol.50 No.44
Drugs & Targets CHMP issues positive opinion of Sarclisa for transplant-ineligible newly diagnosed MM November 22, 2024Vol.50 No.44
